Closed · opens tomorrow 9:30 AM ET
The Marked Chart Wire · Health
BeOne Medicines
BeOne Medicines presented ESMO data for its experimental bispecific antibody. The drug showed a 36 percent confirmed response rate in advanced liver cancer cases with a good safety profile at the Phase 3 dose.
Agenus
Agenus disclosed Sunday that 72 percent of patients with locally advanced dMMR colon cancer showed no residual disease at surgery after six weeks of treatment. The trial also met its primary endpoint, with 83 percent achieving a major pathologic response.
Lung Cancer
Updated findings from a study on first-line non-small cell lung cancer showed lasting benefits when pairing Merck's KEYTRUDA with Eli Lilly's olomorasib.
Pumitamig
BioNTech and Bristol Myers Squibb released Phase 2 data showing a 36.7 percent objective response rate for pumitamig combined with docetaxel in advanced non-small cell lung cancer.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Nubeqa
Orion Corporation stated that adding Nubeqa to standard care significantly lowered the chance of disease spread or mortality in high-risk patients.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.